Controlled trial of adjuvant chemotherapy with melphalan for breast cancer

R D Rubens; J L Hayward; R K Knight; R D Bulbrook; I S Fentiman; M Chaudary; A Howell; H Bush; D Crowther; R A Sellwood; W D George; J M Howat

Controlled trial of adjuvant chemotherapy with melphalan for breast cancer

R D Rubens, J L Hayward, R K Knight, R D Bulbrook, I S Fentiman, M Chaudary, A Howell, H Bush, D Crowther, R A Sellwood, W D George, J M Howat

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

370 patients who had carcinoma of the breast with involved axillary lymph-nodes were randomised after total mastectomy and axillary clearance to receive either no additional treatment or melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles. There was a trend towards longer relapse-free survival (RFS) in patients treated with melphalan, but this was not significant either in the whole series or in sub-groups according to menopausal status or extent of nodal involvement. In patients receiving melphalan RFS was not significantly affected by either the occurrence of amenorrhoea or the dosage of melphalan received. Overall survival did not differ significantly between the two groups. The results of this trial suggest that there is no place for the use of melphalan as adjuvant therapy in the management of early breast cancer.

Original language	English
Pages (from-to)	839-843
Number of pages	5
Journal	Lancet (London, England)
Volume	321
Issue number	8329
Publication status	Published - 16 Apr 1983

Keywords

Adult
Aged
Antineoplastic Agents
Breast Neoplasms
Clinical Trials as Topic
Drug Therapy, Combination
Female
Humans
Mastectomy
Melphalan
Menopause
Middle Aged
Postoperative Care
Quality of Life
Random Allocation
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{582bc2386e4a462ea0804017b26eb9c7,

title = "Controlled trial of adjuvant chemotherapy with melphalan for breast cancer",

abstract = "370 patients who had carcinoma of the breast with involved axillary lymph-nodes were randomised after total mastectomy and axillary clearance to receive either no additional treatment or melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles. There was a trend towards longer relapse-free survival (RFS) in patients treated with melphalan, but this was not significant either in the whole series or in sub-groups according to menopausal status or extent of nodal involvement. In patients receiving melphalan RFS was not significantly affected by either the occurrence of amenorrhoea or the dosage of melphalan received. Overall survival did not differ significantly between the two groups. The results of this trial suggest that there is no place for the use of melphalan as adjuvant therapy in the management of early breast cancer.",

keywords = "Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Therapy, Combination, Female, Humans, Mastectomy, Melphalan, Menopause, Middle Aged, Postoperative Care, Quality of Life, Random Allocation, Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial",

author = "Rubens, {R D} and Hayward, {J L} and Knight, {R K} and Bulbrook, {R D} and Fentiman, {I S} and M Chaudary and A Howell and H Bush and D Crowther and Sellwood, {R A} and George, {W D} and Howat, {J M}",

year = "1983",

month = apr,

day = "16",

language = "English",

volume = "321",

pages = "839--843",

journal = "Lancet (London, England)",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "8329",

}

TY - JOUR

T1 - Controlled trial of adjuvant chemotherapy with melphalan for breast cancer

AU - Rubens, R D

AU - Hayward, J L

AU - Knight, R K

AU - Bulbrook, R D

AU - Fentiman, I S

AU - Chaudary, M

AU - Howell, A

AU - Bush, H

AU - Crowther, D

AU - Sellwood, R A

AU - George, W D

AU - Howat, J M

PY - 1983/4/16

Y1 - 1983/4/16

N2 - 370 patients who had carcinoma of the breast with involved axillary lymph-nodes were randomised after total mastectomy and axillary clearance to receive either no additional treatment or melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles. There was a trend towards longer relapse-free survival (RFS) in patients treated with melphalan, but this was not significant either in the whole series or in sub-groups according to menopausal status or extent of nodal involvement. In patients receiving melphalan RFS was not significantly affected by either the occurrence of amenorrhoea or the dosage of melphalan received. Overall survival did not differ significantly between the two groups. The results of this trial suggest that there is no place for the use of melphalan as adjuvant therapy in the management of early breast cancer.

AB - 370 patients who had carcinoma of the breast with involved axillary lymph-nodes were randomised after total mastectomy and axillary clearance to receive either no additional treatment or melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles. There was a trend towards longer relapse-free survival (RFS) in patients treated with melphalan, but this was not significant either in the whole series or in sub-groups according to menopausal status or extent of nodal involvement. In patients receiving melphalan RFS was not significantly affected by either the occurrence of amenorrhoea or the dosage of melphalan received. Overall survival did not differ significantly between the two groups. The results of this trial suggest that there is no place for the use of melphalan as adjuvant therapy in the management of early breast cancer.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Breast Neoplasms

KW - Clinical Trials as Topic

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Mastectomy

KW - Melphalan

KW - Menopause

KW - Middle Aged

KW - Postoperative Care

KW - Quality of Life

KW - Random Allocation

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

KW - Randomized Controlled Trial

M3 - Article

C2 - 6132179

SN - 0140-6736

VL - 321

SP - 839

EP - 843

JO - Lancet (London, England)

JF - Lancet (London, England)

IS - 8329

ER -

Controlled trial of adjuvant chemotherapy with melphalan for breast cancer

Abstract

Keywords

UN SDGs

Fingerprint

Cite this